{rfName}
Th

Indexed in

License and use

Altmetrics

Analysis of institutional authors

Sancho J-MAuthor

Share

Publications
>
Article

The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study

Publicated to:Cancers. 14 (3): 791- - 2022-02-01 14(3), DOI: 10.3390/cancers14030791

Authors: Zijlstra, JM; Follows, G; Casasnovas, RO; Vermaat, JSP; Kalakonda, N; Choquet, S; Hill, B; Thieblemont, C; Cavallo, F; Cruz, FD; Kuruvilla, J; Hamad, N; Jaeger, U; Caimi, P; Gurion, R; Warzocha, K; Bakhshi, S; Sancho, JM; Schuster, M; Egyed, M; Offner, F; Vassilakopoulos, TP; Samal, P; Ku, MT; Xu, JY; Corona, K; Chamoun, K; Shah, JT; Canales, M; Maerevoet, M

Affiliations

All India Inst Med Sci, Dr BRA Inst Rotary Canc Hosp, Dept Med Oncol, New Delhi 110029, India - Author
Cambridge Univ Hosp NHS Fdn Trust, Dept Haematol, Cambridge CB2 0QQ, England - Author
Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, United States - Author
Case Western Reserve Univ, Case Comprehens Canc Ctr, Sch Med, Cleveland Hts, OH 44106 USA - Author
Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland Hts, OH 44195 USA - Author
Clinical Hermatology Department, Hospital Germans Trias i Pujol, Institut Català d'Oncologia, Universitat Autònoma de Barcelona, Badalona, 08916, Spain - Author
Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, United Kingdom - Author
Department of Haematology, St.Vincent’s Hospital, University of Melbourne, Melbourne, VIC 3065, Australia - Author
Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, United States - Author
Department of Hematology, Amsterdam UMC, Cancer Center, Vrije Universiteit, De Boelelaan 1117, Amsterdam, 1081HV, Netherlands - Author
Department of Hematology, Autonoma University, La Paz University Hospital, Madrid, 28046, Spain - Author
Department of Hematology, Ghent University Hospital, Ghent, 9000, Belgium - Author
Department of Hematology, Institut Jules Bordet, Brussels, 1070, Belgium - Author
Department of Hematology, Instytut Hematologii I Transfuzjologii, Chocimska 5, Warsaw, 00-791, Poland - Author
Department of Hematology, Leiden University Medical Center, Albinesdreef 2, Leiden, 2333 ZA, Netherlands - Author
Department of Hematology, National and Kapodistrian University of Athens, Athens, 15772, Greece - Author
Department of Hematology, St. Vincent’s Hospital Sydney, Darlinghurst, NSW 2010, Australia, St Vincent's Clinical School Sydney, University of New South Wales, Sydney, NSW 2052, Australia, School of Medicine, University of Notre Dame Australia, Fremantl - Author
Department of Hematology, Teaching Hospital Mór Kaposi, Tallian Gy. U 20-32, Kaposvár, H-7400, Hungary - Author
Department of Hematology, University Hospital F. Mitterrand and INSERM 1231, Dijon, 21000, France - Author
Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India - Author
Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, L69 3GE, United Kingdom - Author
Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, A-1090, Austria - Author
Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino/AOU, Città della Salute e della Scienza di Torino, Torino, 10126, Italy - Author
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada - Author
Ghent Univ Hosp, Dept Hematol, B-9000 Ghent, Belgium - Author
Hemato-Oncology, APHP, Saint-Louis Hospital & Paris University, Paris, 75010, France - Author
Hematology Institute, Davidoff Center, Rabin Medical Center, Petach Tikva & Tel-Aviv University, Tel-Aviv, 49100, Israel - Author
Hematology, Hôpital Pitié Salpêtrière, 47-83 Bd de l'Hôpital, Paris, 75013, France - Author
Hematology-Hemato-Oncology, Institute of Medical Sciences & SUM Hospital, Odisha751003, India - Author
Hop La Pitie Salpetriere, Hematol, 47-83 Bd Hop, F-75013 Paris, France - Author
Hosp Univ Virgen Rocio, E-41013 Seville, Spain - Author
Hospital Universitario Virgen del Rocio, Sevilla, E-41013, Spain - Author
INSERM 1231, F-21000 Dijon, France - Author
Inst Hematol & Transfuzjol, Dept Hematol, Chocimska 5, PL-00791 Warsaw, Poland - Author
Inst Med Sci, Hematol Hemato Oncol, Bhubaneswar 751003, Odisha, India - Author
Institut Jules Bordet, Dept Hematol, B-1070 Brussels, Belgium - Author
Karyopharm Therapeut, Newton, MA 02459 USA - Author
Karyopharm Therapeutics, Newton, MA 02459, United States - Author
Leiden Univ, Dept Hematol, Med Ctr, Albinesdreef 2, NL-2333 Leiden, Netherlands - Author
Med Univ Vienna, Dept Med 1, Div Hematol & Hemostaseol, Waehringer Guertel 18-20, A-1090 Vienna, Austria - Author
Natl & Kapodistrian Univ Athens, Dept Hematol, Athens 15772, Greece - Author
Paris Univ, F-75010 Paris, France - Author
Petach Tikva & TelAviv Univ, Rabin Med Ctr, Davidoff Ctr, Inst Hematol, IL-49100 Tel Aviv, Israel - Author
Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada - Author
St Louis Hosp, AP HP, Hematooncol, F-75010 Paris, France - Author
St Vincents Hosp Sydney, Dept Hematol, Darlinghurst, NSW 2010, Australia - Author
Stony Brook Cancer Center, Stony Brook University Hospital, Stony BrookNY 11794, United States - Author
SUM Hosp, Bhubaneswar 751003, Odisha, India - Author
SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA - Author
Teaching Hosp Mor Kaposi, Dept Hematol, Tallian Gy U 20-32, H-7400 Kaposvar, Hungary - Author
Univ Autonoma Barcelona, Inst Catala Oncol, Hosp Germans Trias & Pujol, Clin Hermatol Dept, Badalona 08916, Spain - Author
Univ Autonoma Madrid, La Paz Univ Hosp, Dept Hematol, Madrid 28046, Spain - Author
Univ Hosp F Mitterrand, Dept Hematol, F-21000 Dijon, France - Author
Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool L69 3GE, Merseyside, England - Author
Univ Melbourne, StVincents Hosp, Dept Haematol, Melbourne, Vic 3065, Australia - Author
Univ New South Wales, St Vincents Clin Sch Sydney, Sydney, NSW 2052, Australia - Author
Univ Notre Dame Australia, Sch Med, Fremantle, WA 6160, Australia - Author
Univ Torino AOU, Dept Mol Biotechnol & Hlth Sci, Div Hematol, Citta Salute Sci & Torino, I-10126 Turin, Italy - Author
Vrije Univ, Ctr Canc, Amsterdam UMC, Dept Hematol, Boelelaan 1117, NL-1081HV Amsterdam, Netherlands - Author
See more

Abstract

Keywords

cancerdiffuse large b-cell lymphomaelderly-patientsexportin 1r-choprna exportsadal studyChemotherapy plus rituximabDiffuse large b-cell lymphomaExportin 1Sadal studySelinexor

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Cancers due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 2.44, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jun 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-06-30, the following number of citations:

  • WoS: 1
  • Scopus: 5

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-06-30:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 16.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 16 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 2.75.
  • The number of mentions on the social network X (formerly Twitter): 4 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Australia; Austria; Belgium; Canada; France; Greece; Hungary; India; Israel; Italy; Netherlands; Poland; United Kingdom; United States of America.